Lisa L Barnes1, Ana W Capuano2, Alison E Aiello3, Arlener D Turner4, Robert H Yolken5, E Fuller Torrey5, David A Bennett2. 1. Rush Alzheimer's Disease Center Department of Neurological Sciences Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois. 2. Rush Alzheimer's Disease Center Department of Neurological Sciences. 3. Department of Epidemiology, University of Michigan, Ann Arbor. 4. Rush Alzheimer's Disease Center. 5. The Stanley Medical Research Institute, Chevy Chase, Maryland.
Abstract
BACKGROUND: Human cytomegalovirus (CMV) is prevalent in older adults and has been implicated in many chronic diseases of aging. This study investigated the relation between CMV and the risk of Alzheimer disease (AD). METHODS: Data come from 3 cohort studies that included 849 participants (mean age [±SD], 78.6 ± 7.2 years; mean education duration [±SD], 15.4 ± 3.3 years; 25% black). RESULTS: A solid-phase enzyme-linked immunosorbent assay was used for detecting type-specific immunoglobulin G antibody responses to CMV and herpes simplex virus type 1 (HSV-1) measured in archived serum samples. Of 849 participants, 73.4% had serologic evidence of exposure to CMV (89.0% black and 68.2% white; P < .001). During an average of 5.0 years of follow-up, 93 persons developed AD. CMV seropositivity was associated with an increased risk of AD (relative risk, 2.15; 95% confidence interval, 1.42-3.27) and a faster rate of decline in global cognition (estimate [±standard error], -0.02 ± 0.01; P = .03) in models that controlled for age, sex, education duration, race, vascular risk factors, vascular diseases, and apolipoprotein ε4 level. Results were similar in black and white individuals for both incident AD and change in cognitive function and were independent of HSV-1 status. CONCLUSIONS: These results suggest that CMV infection is associated with an increased risk of AD and a faster rate of cognitive decline in older diverse populations.
BACKGROUND:Human cytomegalovirus (CMV) is prevalent in older adults and has been implicated in many chronic diseases of aging. This study investigated the relation between CMV and the risk of Alzheimer disease (AD). METHODS: Data come from 3 cohort studies that included 849 participants (mean age [±SD], 78.6 ± 7.2 years; mean education duration [±SD], 15.4 ± 3.3 years; 25% black). RESULTS: A solid-phase enzyme-linked immunosorbent assay was used for detecting type-specific immunoglobulin G antibody responses to CMV and herpes simplex virus type 1 (HSV-1) measured in archived serum samples. Of 849 participants, 73.4% had serologic evidence of exposure to CMV (89.0% black and 68.2% white; P < .001). During an average of 5.0 years of follow-up, 93 persons developed AD. CMV seropositivity was associated with an increased risk of AD (relative risk, 2.15; 95% confidence interval, 1.42-3.27) and a faster rate of decline in global cognition (estimate [±standard error], -0.02 ± 0.01; P = .03) in models that controlled for age, sex, education duration, race, vascular risk factors, vascular diseases, and apolipoprotein ε4 level. Results were similar in black and white individuals for both incident AD and change in cognitive function and were independent of HSV-1 status. CONCLUSIONS: These results suggest that CMV infection is associated with an increased risk of AD and a faster rate of cognitive decline in older diverse populations.
Authors: M X Tang; P Cross; H Andrews; D M Jacobs; S Small; K Bell; C Merchant; R Lantigua; R Costa; Y Stern; R Mayeux Journal: Neurology Date: 2001-01-09 Impact factor: 9.910
Authors: Alan J Gow; Charlotte M Firth; Rowan Harrison; John M Starr; Paul Moss; Ian J Deary Journal: Neurobiol Aging Date: 2013-02-22 Impact factor: 4.673
Authors: Nell S Lurain; Barbara A Hanson; Jeffrey Martinson; Sue E Leurgans; Alan L Landay; David A Bennett; Julie A Schneider Journal: J Infect Dis Date: 2013-05-09 Impact factor: 5.226
Authors: Faith Dickerson; Cassie Stallings; Andrea Origoni; Emily Katsafanas; Lucy A B Schweinfurth; Christina L G Savage; Robert Yolken Journal: PLoS One Date: 2014-05-20 Impact factor: 3.240
Authors: Vishwajit L Nimgaonkar; Robert H Yolken; Tianxiu Wang; Chung-Chou H Chang; Lora McClain; Eric McDade; Beth E Snitz; Mary Ganguli Journal: Alzheimer Dis Assoc Disord Date: 2016 Jul-Sep Impact factor: 2.703
Authors: Lisa L Barnes; Ana W Capuano; Allison E Aiello; Arlener D Turner; Robert H Yolken; E Fuller Torrey; David A Bennett Journal: J Infect Dis Date: 2015-01-29 Impact factor: 5.226
Authors: Triptish Bhatia; Joel Wood; Satish Iyengar; Sreelatha S Narayanan; Ram Pratap Beniwal; Konasale M Prasad; Kehui Chen; Robert H Yolken; Faith Dickerson; Ruben C Gur; Raquel E Gur; Smita N Deshpande; Vishwajit L Nimgaonkar Journal: Schizophr Res Date: 2017-08-19 Impact factor: 4.939
Authors: Neill R Graff-Radford; Lilah M Besser; Julia E Crook; Walter A Kukull; Dennis W Dickson Journal: Alzheimers Dement Date: 2016-04-16 Impact factor: 21.566
Authors: Lydia Feinstein; Christian E Douglas; Rebecca C Stebbins; Graham Pawelec; Amanda M Simanek; Allison E Aiello Journal: Mech Ageing Dev Date: 2016-06-04 Impact factor: 5.432
Authors: David A Bennett; Aron S Buchman; Patricia A Boyle; Lisa L Barnes; Robert S Wilson; Julie A Schneider Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472